Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 33 h ago

SUTRO BIOPHARMA, INC.: PERCEPTIVE ADVISORS LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Perceptive Advisors LLC amended its Schedule 13G stake filing for Sutro Biopharma, Inc., according to an SEC filing (accession 0001193125-26-463816). The amendment updates the investment firm's reported beneficial ownership position in the clinical-stage biopharmaceutical company. Schedule 13G filings are used by institutional investors to report passive stakes, and amendments typically signal a change in holdings or related disclosures. The filing did not specify the size or direction of the change in the headline. Investors will watch for further detail on Perceptive's position and any implications for Sutro's shareholder base.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Perceptive Advisors LLC, Sutro Biopharma, Inc.